Belgium-based AgomAb Therapeutics has raised funds in a series A round to support the development of molecular therapies for the regeneration of damaged tissues.
Belgium-based AgomAb Therapeutics has raised funds in a series A round to support the development of molecular therapies for the regeneration of damaged tissues.